Nangibotide (TFA)

Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8) . Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure[1][2][3][4][5].

C56H83F3N14O24S2

1457.46

CC(O)=O.OC(C=C1)=CC=C1C[C@@H](C(NCC(N[C@@H](CS)C(N[C@H](C(N)=O)CCSC)=O)=O)=O)NC([C@H](CCC(O)=O)NC(CNC([C@H](C)NC([C@H](CC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(N)=O)NC([C@@H](N)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O

Apoptosis; Interleukin Related; NF-κB; NOD-like Receptor (NLR) ; TREM receptor

99.86

DMSO : 50 mg/mL (ultrasonic)

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

Blue Ice